Una Health offers a personalised digital therapy that combines biosensor technology with AI to deliver real-time, tailored behavioural interventions for metabolic dysfunction and type 2 diabetes. The product is nutrition-focused and achieved DIGa certification, becoming the first nutrition application for type 2 diabetes approved for full reimbursement in Germany. The company is a remote-first team of ten with seven nationalities, led by co-founders Pascal Grimm (CEO), Dominic Steele (CPO), and Dr. Matthew Fenech (CMO). Una Health positions its approach as holistic, aiming to treat individuals rather than isolated conditions and to address common comorbidities like hypertension and obesity. The team plans to use recent funding to build on success in Germany and expand across Europe and globally, leveraging EU medical device regulations that allow deployment in most of Europe. Their long-term vision is to reverse metabolic dysfunction by creating precise, personalised profiles to identify risk earlier and make lifestyle and medical interventions more effective.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2024